KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash & Equivalents (2016 - 2025)

Evolent Health (EVH) has 11 years of Cash & Equivalents data on record, last reported at $116.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 20.78% year-over-year to $116.6 million; the TTM value through Sep 2025 reached $116.6 million, up 20.78%, while the annual FY2024 figure was $104.2 million, 45.96% down from the prior year.
  • Cash & Equivalents reached $116.6 million in Q3 2025 per EVH's latest filing, down from $151.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $266.3 million in Q4 2021 and bottomed at $96.6 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $177.3 million, with a median of $184.5 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 247.34% in 2021, then plummeted 47.66% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $266.3 million in 2021, then decreased by 29.32% to $188.2 million in 2022, then rose by 2.46% to $192.8 million in 2023, then tumbled by 45.96% to $104.2 million in 2024, then grew by 11.94% to $116.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $116.6 million in Q3 2025, $151.0 million in Q2 2025, and $246.5 million in Q1 2025.